BioCentury | Mar 30, 2018
Product Development

Perception into pain

...a patient subgroup that was more responsive to treatment. The Phase IV IMIOXC study tested oxcarbazepine...
...sensory function -- the “irritable nociceptor phenotype” -- would be more likely to respond to oxcarbazepine...
...organizing principle based on sensory profiles.” Pain (2017) Demant, D., et al. “The effect of oxcarbazepine...
BioCentury | Feb 15, 2016
Analyst Picks & Changes

Analyst picks & changes

...and 7,910,131 by submitting an ANDA to FDA for a generic version of Oxtellar XR oxcarbazepine...
BioCentury | Jan 13, 2014
Finance

Buyside View XXII: 'Grown up' means growth

Stephen Hansen Senior Writer An increase in regulatory approvals and new breakthrough therapies has money managers buying into the concept that biotech has entered a new product cycle that provides a strong fundamental basis for...
BioCentury | Aug 19, 2013
Company News

Supernus, Actavis Inc. neurology news

...U.S. District Court for the District of New Jersey against Actavis regarding Supernus' Oxtellar XR oxcarbazepine...
...which expires on Oct. 29, 2015. In February, Supernus launched the once-daily extended-release formulation of oxcarbazepine...
BioCentury | Jul 15, 2013
Company News

Supernus, Actavis Inc. neurology news

...that Actavis submitted an ANDA to FDA for a generic version of Supernus' Oxtellar XR oxcarbazepine...
...that expires on Oct. 29, 2015. In February, Supernus launched the once-daily extended-release formulation of oxcarbazepine...
BioCentury | Apr 29, 2013
Finance

Highlights of weekly biotech stock moves

...sale of convertible senior secured notes due 2019. Earlier this year, Supernus launched Oxtellar XR oxcarbazepine...
BioCentury | Apr 27, 2013
Financial News

Supernus raises $75 million in note deal

...at $5.30. Supernus proposed the offering late Wednesday. Earlier this year, Supernus launched Oxtellar XR oxcarbazepine...
...adults and children ages 6-17 years old. The product is a once-daily extended-release formulation of oxcarbazepine...
BioCentury | Apr 25, 2013
Financial News

Supernus proposes $75M note deal

...investors of convertible senior secured notes due 2019. Earlier this year, Supernus launched Oxtellar XR oxcarbazepine...
...adults and children ages 6-17 years old. The product is a once-daily extended-release formulation of oxcarbazepine...
BioCentury | Apr 22, 2013
Company News

Daiichi Sankyo, Ranbaxy sales and marketing update

...Brasil Farmaceutica Ltda. Brazilian subsidiary will market Ranbaxy's branded antiepileptic generics Bipogine lamotrigine and Selzic oxcarbazepine...
BioCentury | Feb 11, 2013
Company News

Supernus sales and marketing update

...Supernus launched Oxtellar XR oxcarbazepine in the U.S. as an adjunctive therapy in the treatment of...
...wholesale acquisition cost for a pack of 100 tablets of the once-daily extended-release formulation of oxcarbazepine...
Items per page:
1 - 10 of 63